BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves
A. Doron, Yoav Piura, Ifat Vigiser, Hadar Kolb, Keren Regev, Nahum Nesher, Arnon Karni
Topics & Concepts
MedicineExacerbationCoronavirus disease 2019 (COVID-19)VaccinationMyasthenia gravisPopulationMortality rateInternal medicinePediatricsImmunologyDiseaseInfectious disease (medical specialty)Environmental healthMyasthenia Gravis and ThymomaPeripheral Neuropathies and DisordersAntifungal resistance and susceptibility